Get started
Author

Josep Galcerán

Observed names: J Galcerán, J. M. Galcerán, J.M. Galceran, J.M. Galcerán, Josep Galceran, Josep M Galceran, Josep M Galcerán, Josep M. Galceran, Josep M. Galcerán, Josep Maria Galceran, Josep María Galcerán
Institution: Althaia
Observed institutions: University of Minnesota, Bellvitge University Hospital, Universitat Internacional de Catalunya, Althaia, Minneapolis VA Medical Center, Hospital de Palamós, Universitat de Barcelona
OpenAlex ID: A5108584190
Angiotensin II induces superoxide anion production by mesangial cells
1998 · Edgar A. Jaimes, Josep Maria Galceran, et al. · Kidney International · 272
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
2022 · Peter Rossing, Stefan D. Anker, et al. · Diabetes Care · 242
PDF
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis
2023 · Rajiv Agarwal, Wanzhu Tu, et al. · Annals of Internal Medicine · 125
Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20 000-patient database in Spain
2007 · Manuel Gorostidi, Javier Sobrino, et al. · Journal of Hypertension · 124
Risk factors for non-diabetic renal disease in diabetic patients
2019 · Sheila Bermejo, Ester González, et al. · Clinical Kidney Journal · 47
PDF
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
2022 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care · 41
PDF
Antilymphocyte Globulin Versus OKT3 Induction Therapy in Cadaveric Kidney Transplantation: A Prospective Randomized Study
1992 · Josep M. Grino, Alberto M. Castelao, et al. · American Journal of Kidney Diseases · 41
Design and patient characteristics of ESHOL study, a Catalonian prospective randomized study
2010 · Francisco Maduell, Francesc Moreso, et al. · Journal of Nephrology · 23
Increased mortality after kidney transplantation in mildly frail recipients
2022 · María José Pérez-Sáez, Carlos E Arias-Cabrales, et al. · Clinical Kidney Journal · 21
PDF
Morbimortalidad cardiovascular y patrones geométricos del ventrículo izquierdo en pacientes hipertensos atendidos en atención primaria
2009 · Francisco J. Tovillas-Morán, Edurne Zabaleta-del-Olmo, et al. · Revista Española de Cardiología · 20
Role of dihydropyridinic calcium channel blockers in the management of hypertension
2012 · Antonio Coca, Pilar Mazón, et al. · Expert Review of Cardiovascular Therapy · 19
Cardiovascular Morbidity and Mortality and Left Ventricular Geometric Patterns in Hypertensive Patients Treated in Primary Care
2009 · Francisco J. Tovillas-Morán, Edurne Zabaleta-del-Olmo, et al. · Revista Española de Cardiología (English Edition) · 15
Percutaneous transluminal angioplasty in the treatment of renovascular hypertension.
1991 · A Martinez-Amenós, H Rama, et al. · PubMed · 14
Manidipine treatment in patients with albuminuria not sufficiently reduced with renin–angiotensin system blockers
2010 · Josep Galceran, Jaume Plana, et al. · Expert Review of Cardiovascular Therapy · 12
Morbilidad y mortalidad cardiovascular y criterios electrocardiográficos de hipertrofia ventricular izquierda en pacientes hipertensos en atención primaria
2010 · Francisco Javier Tovillas-Morán, Miguel Vilaplana-Cosculluela, et al. · Medicina Clínica · 9
Documento de Consenso sobre Hipertensión Arterial y Anestesia de las Sociedades Catalanas de Anestesiología e Hipertensión Arterial
2009 · P. Sierra, J.M. Galcerán, et al. · Revista Española de Anestesiología y Reanimación · 8
Frailty and sarcopenia metabolomic signatures in kidney transplant candidates: the FRAILMar study
2024 · Francisco Madrid-Gambin, María José Pérez-Sáez, et al. · Clinical Kidney Journal · 6
PDF
Estudio transversal comparativo de las fórmulas CKD-EPI y MDRD-4 a partir de la historia clínica informatizada de Atención Primaria de Barcelona
2012 · J.M. Elorza-Ricart, F.J. Tovillas-Morán, et al. · Hipertensión y Riesgo Vascular · 6
Effect of Ciclosporin on Serum Lipids and Modification with LSL 90202, a Lysine Salt of Eicosapentaenoic Acid
2008 · J. Torras, I. Herrero, et al. · The Nephron journals/Nephron journals · 3
Documento de consenso sobre hipertensión arterial y anestesia de las Sociedades Catalanas de Anestesiología e Hipertensión Arterial
2009 · P. Sierra, J.M. Galcerán, et al. · Hipertensión y Riesgo Vascular · 2
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897
2023 · Peter Rossing, Ellen Burgess, et al. · Diabetes Care · 1
PDF
Hypertension and Vascular Risk: A New step forward
2022 · P. Armario, E. Vinyoles, et al. · Hipertensión y Riesgo Vascular · 1
Riesgo por enfermedad renal crónica: la epidemia revisada
2010 · J.M. Galcerán · Hipertensión y Riesgo Vascular · 1
Prevalencia de disfunción diastólica en los pacientes hipertensos de nuevo diagnóstico y sin tratamiento
2006 · J. Plana, T. Poblet, et al. · Hipertensión y Riesgo Vascular · 1
Hypertension and Vascular Risk already has an impact factor. Now a new challenge begins
2024 · P. Armario, E. Vinyoles, et al. · Hipertensión y Riesgo Vascular
Works count: 30
Citation count: 1,054
H-index: 13
I10-index: 14
Year
Topic
Type